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Background: In Parkinson’s disease (PD), impulse control disorders (ICDs) develop
as side-effect of dopaminergic replacement therapy (DRT). Cognitive, affective, and
motivational correlates of ICD in medicated PD patients are debated. Here, we
systematically reviewed and meta-analyzed the evidence for an association between ICD
in PD and cognitive, affective, and motivational abnormalities.
Methods: A systematic review and meta-analysis was performed on PubMed, Science
Direct, ISI Web of Science, Cochrane, EBSCO for studies published between 1-1-2000
and 8-3-2017 comparing cognitive, affective, and motivational measures in PD patients
with ICD (ICD+) vs. those without ICD (ICD–). Exclusion criteria were conditions other
than PD, substance and/or alcohol abuse, dementia, drug naïve patients, cognition
assessed by self-report tools. Standardized mean difference (SMD) was used, and
random-effect model applied.
Results: 10,200 studies were screened (title, abstract), 79 full-texts were assessed, and
25 were included (ICD+: 625 patients; ICD–: 938). Compared to ICD–, ICD+ showed
worse performance reward-related decision-making (0.42 [0.02, 0.82], p = 0.04) and
set-shifting tasks (SMD = −0.49 [95% CI −0.78, −0.21], p = 0.0008). ICD in PD was
also related to higher self-reported rate of depression (0.35 [0.16, 0.54], p = 0.0004),
anxiety (0.43 [0.18, 0.68], p = 0.0007), anhedonia (0.26 [0.01, 0.50], p = 0.04), and
impulsivity (0.79 [0.50, 1.09], p < 0.00001). Heterogeneity was low to moderate, except
for depression (I2 = 61%) and anxiety (I2 = 58%).
Conclusions: ICD in PD is associated with worse set-shifting and reward-related
decision-making, and increased depression, anxiety, anhedonia, and impulsivity. This is
an important area for further studies as ICDs have negative impact on the quality of life
of patients and their caregivers.
Keywords: Parkinson’s disease, impulse control disorder, cognition, affective factors, motivation, impulsivity,
meta-analysis, depression
Martini et al. PD, ICD and Cognition
INTRODUCTION
Impulse control disorders (ICDs), such as pathological gambling,
hypersexuality, binge-eating, and compulsive shopping, can
occur in over 13% of medicated Parkinson’s disease (PD) patients
(1). Although ICDs are recognized as side-effect of dopamine
replacement therapy (DRT), mainly D2 dopamine agonists and
levodopa, their pathophysiology is unclear.
It has been hypothesized that, in vulnerable individuals,
DRT used to restore dopamine levels in nigrostriatal circuitry
may overstimulate the less severely affected mesocorticolimbic
circuitry (2). Mesocorticolimbic overstimulation may disrupt
prefrontal-dependent executive function, affect and motivation
and thus increase vulnerability to ICD. According to this view, in
medicated PD patients, we should expect a correlation between
ICD and cognitive, affective and motivational factors. However,
data in the literature are inconclusive.
Studies on cognition, affective processing and motivation
conducted in small cohorts of PD patients with and without
ICD (i.e., n: 17–155 patients) yielded inconsistent findings
with respect to frontal cognitive abilities in PD patients with
ICD. Some studies reported worse performance in executive
function, including set-shifting (3–7), working memory (8),
concept formation and reasoning (5, 7), and reward-related
decision-making (9–15) in PD with ICD (ICD+) compared to
PD without ICD (ICD-). Conversely, other studies found similar
performances for inhibition (9, 16–18), set-shifting (19, 20),
working memory (3, 11, 17, 21, 22), and reward-related decision-
making (16, 17, 20, 23). Finally, a single study reported better
executive functions in ICD+ (24). Reports on affective factors
are also inconclusive, as self-reported depression and anxiety
were sometimes found to be associated with ICD (18, 20, 21,
25–28), and sometimes not (3–6, 17, 19, 22, 29–31). However,
motivational factors such as self-reported apathy (11, 21, 27, 28),
anhedonia (27, 32), and impulsivity (17, 20–22, 32) appeared to
be elevated in ICD+ vs. ICD–.
A recent meta-analysis identified several cognitive
subdomains (i.e., concept formation, set-shifting, reward-
related decision-making, and visuospatial abilities) to be worse
in ICD+ vs. ICD– (33), but it included a mixed sample of
medicated and drug naïve patients that did not allow to explore
the relationship between cognitive disturbances, DRT and ICD.
Moreover, it included patients with comorbidities for
substance abuse and/or dementia, two factors that could
be independently associated with cognitive changes. Finally,
the relationship between cognition-emotion and cognition-
motivation, critical to understanding the broader context in
which ICDs develop, was not explored in the previous meta-
analysis (34).
To reconcile discordant findings in the literature about
cognitive, affective and motivational correlates of ICD in
Abbreviations: DBS, deep brain stimulation; DRT, dopamine replacement
treatment; H and Y, Hoehn and Yahr scale; ICD, impulse control disorder; LEDD,
levodopa equivalent daily dose; PD, Parkinson’s disease; QUIP, Questionnaire
for Impulsive-Compulsive Disorders in Parkinson’s Disease; SDM, standardized
mean difference; STN-DBS, sub thalamic nucleus deep brain stimulation; UPRDS,
Unified Parkinson’s Disease Rating Scale.
medicated PD patients, a systematic review and meta-analysis
was conducted. Moreover, this work is meant to address the
issues of a previous meta-analysis and to offer new information
on this topic. To this aim, we applied stricter inclusion and
exclusion criteria, by including only studies on PD patients
under DRT at the time of assessment and free from co-morbid
substance abuse and/or dementia. Moreover, we included studies
with affective and motivational measures, so that any cognitive
change could be interpreted within the broader context of
cognition-emotion and cognition-motivation relationships (34).
A clear understanding of cognitive, affective and motivational
changes in ICD may indirectly increase our understanding of
ICD pathophysiology and in turn its management.
METHODS
Study Design, Participants, and
Comparators
A systematic review and meta-analysis were performed to
identify cognitive, affective and motivational factors associated
with ICD in PD under DRT (ICD+). The comparator group was
patients with PD but no ICD (ICD–).
Search Strategy and Selection Criteria
On June 26th 2016, PubMed, Science Direct, ISI Web of Science,
Cochrane, EBSCO were searched for peer-reviewed papers in
English, Italian and Spanish published since January 2000,
when the first report of ICD development after dopaminergic
medication initiation was reported (35). The systematic review
was further updated on March 8th 2017.
Studies were identified using the following string (36) in
PubMed: “(Parkinson’s disease) AND (impulse control disorders
OR impulsivity OR cognition OR decision-making).” The search
strategy for the other databases included (Parkinson’s disease)
AND (impulse control disorders), then (Parkinson’s disease)
AND (impulsivity), then (Parkinson’s disease) AND (cognition),
and (Parkinson’s disease) AND (decision-making). A total of
40,672 papers were identified. After exclusion of duplicates,
10,200 papers were title and abstract screened.
Studies were included if: (a) PD patients were under DRT;
(b) ICD assessment was performed in a reliable manner
with the Questionnaire for Impulsive-Compulsive Disorders in
Parkinson’s Disease (QUIP), the QUIP rating scale (QUIP-rs),
the Minnesota Impulse Disorders Interview, clinical interview
based on diagnostic criteria, or a combination of these; (c)
performances of PD patients with ICD (ICD+) were compared
with those with PD but no history of ICD (ICD–); (d) cognitive,
affective, and/or motivational measures were reported. A further
inclusion criterion was independence of samples. Only baseline
data for prospective studies and the study with the largest
sample for multiple studies published by the same author(s) were
included.
We excluded reviews, case studies, commentaries, letters,
abstracts and dissertations, and postal surveys. Studies including
drug naïve PD patients were also excluded since we were
interested in ICD developed as a DRT side-effect. Studies in
which PD patients underwent non-pharmacological treatments
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FIGURE 1 | PRISMA diagram of the study (www.prisma-statement.org). DRT, dopaminergic replacement treatment; ICD, impulse control disorder; ICD+, PD patients
with ICD; ICD–, PD patients without ICD; PD, Parkinson’s disease.
such as deep brain stimulation (DBS) were excluded. This
criterion was based on controversial reports of either ICD
amelioration or ICD appearance after DBS (37), and the notion
that DBS may worsen some cognitive outcomes (38). Studies
including participants with dementia and drug/alcohol abuse
were excluded, as these conditions might be independently
associated with cognitive and neuropsychiatric changes. Other
exclusion criteria were: cognition assessed by self-report
measures or by general screening tools (e.g., Mini-Mental State
Examination) because of their limited specificity and sensitivity
(39). Studies focusing on dopamine dysregulation syndrome
and/or punding only were not included since these conditions
are considered different from ICD, as they are more common in
patients with advanced PD, cognitive impairment and dementia
(40). However, screening questionnaires (e.g., QUIP, QUIP-rs)
include dopamine dysregulation syndrome and punding, and
some ICD+ patients we included may have had these conditions
too, in addition to ICD. Finally, to ensure that the ICD- group
included patients without any type of ICD, studies not assessing
all ICD types (e.g., using only the South Oaks Gambling Screen)
were excluded.
Data Extraction
Following exclusion of duplicate and irrelevant articles through
title and abstract screening, 79 papers were included for full-
text evaluation. Reference lists of these studies were manually
searched to identify additional relevant articles, and two papers
were included at this stage.
Two reviewers (AM, DDL) independently screened titles
and abstracts using Rayyan software (41), and three reviewers
(AM, DDL, ST) independently evaluated papers selected for
full-text examination. Disagreements were resolved through
discussions. Disagreement concerned one paper (42) over the
75 selected for full-text examination (inter-rater agreement:
98.67%). Twenty-five articles were included for quantitative
analysis (Figure 1).
Corresponding authors of five studies were contacted for
exact data. Means and standard deviations were obtained
for two studies, which reported median and interquartile
ranges (20, 25), according to a proposed formula (43). Two
reviewers (AM, DDL) independently extracted the following
data: sample size, age at evaluation, age at PD onset, PD duration,
education (years), Hoehn and Yahr (H and Y) stage, Unified
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Parkinson’s Disease Rating Scale motor section (UPDRS-III)
ON-medication, depression, antidepressants use, antipsychotics
use, total levodopa equivalent daily dose (LEDD, mg), levodopa
LEDD, dopamine agonist LEDD, outcomes, ICD screening tool,
ICD type, and statistics.
Primary outcomes were cognitive, affective, and motivational
scores. Cognitive tests were categorized on the basis of the
main cognitive process involved (44). The categories were
“memory”(short-term verbal and visuospatial memory, long-
term verbal and visuospatial memory); “working memory”;
“attention”; “executive function” (concept formation and
reasoning, concept formation sort and shift, set-shifting,
inhibition, cognitive flexibility, reward-related decision-
making); “visuospatial abilities”; “language”; “apraxia”; “novelty
seeking”; “incentive salience” and “data gathering.” Concept
formation and reasoning relates to the development of ideas
based on the common properties of objects, events, or qualities
using abstraction and generalization processes whilst concept
formation sort and shift requires to form a sorting principles
and apply it (sort), and then abandon it and switch to a different
principle (shift) (44).
Affective and motivational measures were categorized
as depression, anxiety, anhedonia, apathy, and
impulsivity.
Cognitive processes assessed in a single study (i.e., novelty
seeking, incentive salience, data gathering, apraxia) were not
included in the meta-analysis. When a study reported multiple
measures for the same outcome, the most relevant one was
chosen by two reviewers with expertise on neuropsychological
assessment (AM, DDL).
Data Analysis
Data were analyzed using ReviewManager v5.3 (45). Effect size
was estimated as standardized mean difference (SMD), which is
comparable to Hedges’ adjusted g value. Effect sizes of 0.2, 0.5,
and 0.8 or more are considered as small, moderate and large,
respectively (46). Cochran’s Q (χ2) was used to test heterogeneity
between studies. The degree of heterogeneity was quantified by
I2, which values range between 0 and 100%. I2 percentages of
25, 50, 75 are considered as low, moderate and high, respectively
(47). Random-effect model was applied, as patients differ in
clinical (e.g., UPDRS-III ON medication range: 10.9–36.7) and
demographic characteristics (e.g., age range: 54.6–71.4), therefore
the true effect may vary from study to study. In contrast to
fixed-effect models, random-effect models consider both within
and between study variances. As heterogeneity was moderate
to high for some outcomes (i.e., working memory, depression,
anxiety, and apathy), the consequences of applying a fixed-
effect model, which does not consider between studies variance,
may result in type I error rate inflation (48). Conversely, if
random-effect models are applied with effect sizes that vary
only due to sampling error as when heterogeneity is low (i.e.,
short-term visuospatial memory, attention, concept formation
reasoning, anhedonia), the consequences are less dramatic (e.g.,
using Hedges’ method, the additional between-study effect size
variance used in the random effect method becomes zero
when sample effect sizes are homogeneous, yielding the same
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TABLE 2 | Cognitive subdomains and tasks used in the studies included in the meta-analysis.
Cognitive subdomain Cognitive tasks References
Short-term verbal memory CVLT-II immediate Erga et al. (18)
Digit Span Forward Biundo et al. (3, 4); Housden et al. (11); Bentivoglio et al.
(17); Piray et al. (22); Merola et al. (42)
RAVLT—immediate Tessitore et al. (5); Vitale et al. (6); Pontieri et al. (27)
Short-term visuospatial memory CBTT Biundo et al. (3, 4); Tessitore et al. (5); Bentivoglio et al.
(17); Merola et al. (42)
Long-term verbal memory CVLT-II delayed
HVLT-R delayed
Paired associate learning
Prose Memory
Erga et al. (18)
Mack et al. (19)
Merola et al. (42)
Biundo et al. (4)
RAVLT- delayed Biundo et al. (3); Tessitore et al. (5); Vitale et al. (6);
Bentivoglio et al. (17); Pontieri et al. (27)
Long-term visuospatial memory ROCF—delayed Biundo et al. (3, 4); Pontieri et al. (27)
Working memory Digit Ordering Test Biundo et al. (4)
Digit Span Backward Biundo et al. (3); Djamshidian et al. (8); Housden et al.
(11); Bentivoglio et al. (17); Piray et al. (22)
n-Back Leroi et al. (21)
Attention Attentive Matrices Tessitore et al. (5); Vitale et al. (6)
Conner’s Performance Test Pineau et al. (20)
Double barrage—accuracy Bentivoglio et al. (17)
TMT-A Biundo et al. (3, 4); Mack et al. (19); Merola et al. (42)
Set-shifting TMT-B Biundo et al. (3, 4); Tessitore et al. (5); Mack et al.
(19); Merola et al. (42)
TMT- B-A Vitale et al. (6); Pineau et al. (20)
Concept formation (sort and shift) MWCST—categories Rossi et al. (10); Bentivoglio et al. (17); Pineau et al. (20);
Pontieri et al. (27); Merola et al. (42)
WCST—global score Vitale et al. (6); Tessitore et al. (5)
Concept formation (reasoning) RCPM
RPM
Biundo et al. (3); Tessitore et al. (5); Bentivoglio et al. (17);
Merola et al. (42)
Cilia et al. (30)
Inhibition Go/no-Go—errors Rossi et al. (10)
Stop Signal Task Claassen et al. (31)
Stroop errors Biundo et al. (3, 4); Vitale et al. (6);Djamshidian et al.
(9); Bentivoglio et al. (17)
Stroop time Tessitore et al. (5); Cera et al. (16); Erga et al. (18);
Pontieri et al. (27)
Cognitive flexibility Phonological Fluency Biundo et al. (3, 4); Tessitore et al. (5); Bentivoglio et al.
(17); Erga et al. (18); Mack et al. (19); Leroi et al. (21);
Pineau et al. (20); Pontieri et al. (27); Merola et al. (42)
Reward-related decision-making IGT Rossi et al. (10); Bentivoglio et al. (17); Pineau et al.
(20)
KDDQ Housden et al. (11); Joutsa et al. (23)
Monetary risk taking Cera et al. (16)
Probabilistic Reward Piray et al. (22)
Risk Task Djamshidian et al. (8)
Visuospatial abilities Constructional apraxia Bentivoglio et al. (17)
ROCF—copy Biundo et al. (3, 4); Tessitore et al. (5); Vitale et al. (6);
Pontieri et al. (27)
VOSP—silhuette Erga et al. (18)
Language Naming Biundo et al. (4)
Oral Verbal Naming Bentivoglio et al. (17)
(Continued)
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TABLE 2 | Continued
Affective and Motivational Self-report measures References
Depression BDI Biundo et al. (3, 4); Housden et al. (11); Mack et al. (19);
Piray et al. (22); Vela et al. (25); Wu et al. (26); Merola
et al. (42)
CESD Claassen et al. (31)
GDS Cilia et al. (30)
HADS-D Vitale et al. (6); Leroi et al. (21); O’Sullivan et al. (28, 29)
HAM-D Tessitore et al. (5); Bentivoglio et al. (17); Pontieri et al.
(27); Pettorruso et al. (32)
MADRS Rossi et al. (10); Erga et al. (18); Pineau et al. (20)
Anxiety HADS-A Tessitore et al. (5); Vitale et al. (6); Leroi et al. (21);
O’Sullivan et al. (28, 29)
HAM-A Bentivoglio et al. (17); Pontieri et al. (27); Pettorruso et al.
(32)
STAI-state Housden et al. (11); Merola et al. (42)
Anhedonia SHAPS Pontieri et al. (27); Pettorruso et al. (32)
Apathy AES-C Leroi et al. (21); Merola et al. (42)
Starkstein Apathy Scale Pineau et al. (20); Pontieri et al. (27)
Impulsivity BIS-11 Bentivoglio et al. (17); Pineau et al. (20); Leroi et al. (21);
Piray et al. (22); Pettorruso et al. (32)
BSCS O’Sullivan et al. (29)
AES-C, Apathy evaluation scale by a clinician; BDI, Beck depression inventory; BIS-11, Barrat impulsiveness scale-11; BSCS, brief self-control scale; CBTT, Corsi’s block-tapping
test; CVLT-II, California verbal learning test II; CESD, Centre for Epidemiological Studies-Depression scale; GDS, Geriatric depression scale; HADS-A, Hospital anxiety and depression
scale-anxiety subscale; HADS-D, Hospital anxiety and depression scale-depression subscale; HAM-A, Hamilton rating scale for anxiety; HAM-D, Hamilton rating scale for depression;
HVLT-R, Hopkins verbal learning test revised; IGT, Iowa gambling task; KDDQ, Kirby delayed discounting questionnaire; MADRS, Montgomery-Asberg depression rating scale; MWCST,
modified Wisconsin card sorting test; RAVLT, Rey’s auditory verbal learning test; RCPM, Raven’s colored progressive matrices; ROCF, Rey-Osterrieth complex figure test; RPM, Raven’s
progressive matrices; SHAPS, Snaith-Hamilton pleasure scale; STAI-state, state-trait anxiety inventory; TMT-A, trail making test part A; TMT-B, trail making test part B; VOSP, visual
object and space perception battery; WCST, Wisconsin card sorting test. In bold scores that have been reversed in order to obtain scores with the same meaning (e.g., higher scores
better performances).
result as the fixed effect method) (48). Moreover, following
this approach, studies were not excluded because of their
small sample size, because in random-effect models effect sizes
are weighed by their variance, which is higher in smaller
studies.
Two authors independently explored funnel plots for
publication bias (AM, DDL), and incongruences were resolved
by discussion with two other authors (ST, JAG). Funnel plots
of outcomes with less than ten studies were not inspected
since the power is too low to discriminate publication bias’s
asymmetry from chance (49). Blinding of assessors (performance
bias) and incomplete data outcome (attrition bias) were
independently assessed for each study as “low risk,” “high
risk,” or “unclear” by two reviewers (AM, DDL) following
Cochrane Collaboration recommendations. Sensitivity analysis
was performed by excluding one study at time and verifying
its impact on the overall effect size. Sensitivity analysis was not
performed for outcomes with two studies. Moderator analysis
via meta-regression was performed using SPSS version 21.0
(50). We tested the hypothesis that variation among studies
in effect size was associated with differences in age, years of
education, disease duration, UPDRS-III score, H and Y score,
total LEDD, levodopa LEDD, and dopamine agonist LEDD. As
suggested by Borenstein (51), moderator analysis was conducted
only for outcomes in which there were at least 10 studies to one
covariate.
RESULTS
After removal of duplicates, 10,200 records were screened by title
and abstract, 79 full-text articles were assessed for eligibility, and
54 were excluded (Figure 1). Twenty-five studies were included
in the meta-analysis (Table 1).
Four studies investigated cognitive performance without
affective and motivational outcomes (8, 9, 16, 23), 17 studies
included both cognitive, affective and motivational outcomes
(3–6); (10, 11, 17–22); (27, 30–32, 50), and four studies included
affective andmotivational data only (25, 26, 28, 29). Three studies
divided ICD+ in two groups: PD patients with pathological
gambling and those with ICD other than pathological gambling
(16, 27, 32), and one study divided the ICD+ in multiple and
single ICD groups (26). As the comparison between ICD subtypes
was not relevant in our meta-analysis, sub-groups were merged
by calculating the pooled means and standard deviations. In one
study (6) ICD+ group was divided in pathological gambling,
binge-eating, hypersexuality and multiple ICD sub-groups. Since
seven PD patients belonging to either the pathological gambling
or the binge-eating sub-groups developed ICD before DRT
initiation, only data from hypersexuality and multiple ICD sub-
groups were extracted and merged as described above. Six
studies focused on neuroimaging outcomes but also provided
affective (26) and cognitive measures (3–5); (23, 30). One study
retrospectively investigated persistent, remitting, and new-onset
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FIGURE 2 | Forest plots for memory. Here are reported forest plots for short-term (verbal, (A) visuospatial, (B) and long-term (verbal, (C); visuospatial, (D) memory
outcomes. Standardized mean difference represents Hedges’s g effect size. The size of the square indicates the weight of the study. The horizontal line represents the
95% confidence interval. The diamond represents the pooled effect size. Negative effect sizes indicate worse performance in PD patients with ICD (ICD+) in
comparison to those without ICD (ICD–). ICD, impulse control disorder; PD, Parkinson’s disease.
ICD before and after subthalamic nucleus DBS (STN-DBS) (42).
For this study, only pre-STN-DBS data of persistent and never
experienced ICD were included in the meta-analysis. Despite
the fact that dementia was not explicitly excluded (42), data
were included because STN-DBS is performed in non-demented
patients only.
The meta-analysis includes 1,563 subjects. The ICD+ group
was composed of 625 patients (mean age range: 54.6–68.7
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FIGURE 3 | Forest plots for working memory and attention. Here are reported forest plots for working memory (A) and attention (B). Standardized mean difference
represents Hedges’s g effect size. The size of the square indicates the weight of the study. The horizontal line represents the 95% confidence interval. The diamond
represents the pooled effect size. Negative effect sizes indicate worse performance in PD patients with ICD (ICD+) in comparison to those without ICD (ICD−). ICD,
impulse control disorder; PD, Parkinson’s disease.
years; mean PD duration: 2.4–14.3 years; mean H and Y:
1.3–2.8; mean UPDRS-III score ON medication: 10.9–36.7).
The ICD– group included 938 patients (mean age: 55–71.4
years; mean PD duration: 2.3–13.1 years; mean H and Y
stage: 1.4–2.5; mean UPDRS-III score ON medication: 11.7–
32.3).
Fourteen meta-analyses were performed to compare cognitive
outcomes and five to compare affective and motivational
measures in ICD+ compared to ICD– groups.
The following cognitive outcomes were explored: short-
term verbal and visuospatial memory, long-term verbal
and visuospatial memory, working memory, attention,
set-shifting, concept formation (reasoning, sort and shift),
inhibition, cognitive flexibility, reward-related decision-making,
visuospatial abilities, and language (Table 2).
ICD+ showed worse performance in set-shifting
(SMD = −0.49; 95% CI: −0.78, −0.21; Z = 3.37; p = 0.0008)
and reward-related decision-making (SMD = 0.42; 95%
CI: 0.02, 0.82; Z = 2.05; p = 0.04). The heterogeneity
was low-to-moderate for set-shifting (χ2 = 9.32, p = 0.16,
I2 = 36%) and moderate for reward-related decision-making
(χ2 = 15.50, p = 0.03, I2 = 55%). Effect sizes for the
other cognitive outcomes did not differ significantly between
groups. Heterogeneity was low for short-term visuospatial
memory, attention, concept formation (reasoning), moderate
for cognitive flexibility, concept formation (sort and shift),
and language, high for short-term verbal memory, long-term
verbal memory, long-term visuospatial memory, visuospatial
abilities, and inhibition, moderate-to-high for working memory
(Figures 2–6).
The following self-reported affective and behavior outcomes
were explored: depression, anxiety, anhedonia, apathy, and
impulsivity. ICD+ showed increased depression (SMD = 0.35;
95% CI: 0.16, 0.54; Z = 3.54; p = 0.0004), anxiety (SMD = 0.43;
95% CI: 0.18, 0.68; Z = 3.39; p = 0.0007), anhedonia
(SMD = 0.26; 95% CI: 0.01, 0.50; Z = 2.01; p = 0.04), and
impulsivity (SMD = 0.79; 95% CI: 0.50, 1.09; Z = 5.26;
p < 0.00001), but comparable apathy symptoms (Figure 7).
Heterogeneity was low for anhedonia (χ2 = 0.01, p = 0.94,
I2 = 0%), moderate for impulsivity (χ2 = 8.89, p = 0.11,
I2 = 44%), and moderate-to-high for depression (χ2 = 51.42,
p= 0.0001, I2 = 61%), anxiety (χ2 = 21.27, p= 0.01, I2 = 58%),
and apathy (χ2 = 9.09, p = 0.03, I2 = 67%; Figure 7). Results of
the meta-analyses are summarized in Table 3.
Risk of Bias
Visual exploration of funnel plots did not suggest possible
publication bias for short-term verbal memory, inhibition,
cognitive flexibility, depression, and anxiety that were the only
outcomes with at least 10 studies (Figure 8).
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FIGURE 4 | Forest plots for executive functions set-shifting and concept formation. Here are reported forest plots for set-shifting (A), and concept formation
(reasoning, B; sort and shift, C).
Risk of performance bias was unclear with only 2/25 studies
indicating assessors blinding procedures.
Attrition bias was low, with 4/25 studies with missing data.
Sensitivity Analysis and Moderator
Analysis
Sensitivity analysis showed that after removing Pontieri et al.
(27), the overall effect size of long-term visuospatial memory
became significant (SMD = −0.44; 95% CI: −0.75, −0.13;
Z = 2.81; p = 0.005) and the heterogeneity changed from high
(χ2 = 6.64, p = 0.04, I2 = 70%) to low (χ2 = 0.62, p = 0.43,
I2 = 0%). After removing Biundo et al. (3), the overall effect
size of working memory became significant (SMD=−0.32; 95%
CI: −0.63, −0.01; Z = 2.05; p = 0.04) and the heterogeneity
changed from high (χ2 = 14.73, p = 0.02, I2 = 59%) to
moderate (χ2 = 8.41, p = 0.13, I2 = 41%). The overall effect
size of attention became significant after removing Merola
et al. (42) (SMD = −0.27; 95% CI: −0.50, −0.04; Z = 2.29;
p = 0.02), but heterogeneity remained low. The overall effect
size of inhibition became significant after removing Biundo
et al. (4) (SMD = −0.34; 95% CI: −0.65, −0.03; Z = 2.18;
p = 0.03) and heterogeneity changed from high to moderate-
to-high (χ2 = 24.18, p = 0.004, I2 = 63%). The overall effect
size of reward-related decision-making lost significance after
removing Bentivoglio et al. (17) (SMD = 0.42; 95% CI: −0.05,
0.89; Z = 1.75; p = 0.08), Housden et al. (11) (SMD = 0.36;
95% CI: −0.08, 0.81; Z = 1.59; p = 0.11), Piray et al. (22)
(SMD = 0.35; 95% CI: −0.08, 0.78; Z = 1.58; p = 0.11), and
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FIGURE 5 | Forest plots for executive functions inhibition, cognitive flexibility, and reward-related decision-making. Here are reported forest plots for inhibition (A),
cognitive flexibility (B), and reward-related decision-making (C). Standardized mean difference represents Hedges’s g effect size. The size of the square indicates the
weight of the study. The horizontal line represents the 95% confidence interval. The diamond represents the pooled effect size. Negative effect sizes indicate worse
performance in PD patients with ICD (ICD+) in comparison to those without ICD (ICD–). ICD, impulse control disorder; PD, Parkinson’s disease.
Rossi et al. (10) (SMD = 0.29; 95% CI: −0.03, 0.61; Z = 1.78;
p= 0.07). After removing Rossi et al. (10), heterogeneity changed
from moderate (χ2 = 15.50, p = 0.03, I2 = 55%) to low
(χ2 = 8.27, p = 0.22, I2 = 27%). Including or excluding the
other studies did not change heterogeneity. The overall effect size
of apathy became significant after removing Pontieri et al. (27)
(SMD = 0.60; 95% CI: 0.25, 0.95; Z = 3.38; p = 0.0007) and
heterogeneity changed from high (χ2 = 9.09, p= 0.03, I2 = 67%)
to low (χ2 = 2.07, p = 0.35, I2 = 4%). Moderator analysis was
performed for short-term verbal memory, inhibition, cognitive
flexibility, and depression, which were the only outcomes that
included at least 10 studies each (51). Anxiety did not undergo
moderator analysis, because none of the covariates of interest
were assessed in at least 10 studies. Moderator analysis showed
no effect of age, education, PD duration, H and Y, UPDRS-III,
and total LEDD, levodopa LEDD, dopamine agonist LEDD on
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FIGURE 6 | Forest plots for visuospatial abilities and language. Here are reported forest plots for visuospatial abilities (A) and language (B). Standardized mean
difference represents Hedges’s g effect size. The size of the square indicates the weight of the study. The horizontal line represents the 95% confidence interval. The
diamond represents the pooled effect size. Negative effect sizes indicate worse performance in PD patients with ICD (ICD+) in comparison to those without ICD
(ICD−). ICD, impulse control disorder; PD, Parkinson’s disease.
short-term verbal memory, inhibition, cognitive flexibility, and
depression (Table 4).
DISCUSSION
The primary aim of this meta-analysis of 25 studies was to
describe the pattern of cognitive function in DRT-medicated
ICD+ compared to ICD–. A stricter set of inclusion criteria was
applied than used previously (33), to achieve amore homogenous
ICD+ group, and a better understanding of the relationship
between ICD and cognition in medicated PD. A secondary aim
was to examine affective and motivational correlates of ICD, as
emotion-cognition and motivation-cognition relationships are
receiving increasing attention to understand psychopathology
and improve pharmacological and psychological treatments (34).
Our findings suggest ICD to be associated with worse
performance on a set of executive function measures assessing
set-shifting (Trail Making Test part B, and B-A) and reward-
related decision-making (Iowa Gambling Task, Monetary Risk
Task, Kirby Delay Discounting Questionnaire), with relative
sparing of other executive tasks that assess concept formation
and reasoning (Raven’s progressive matrices standard and
colored versions), concept formation sort and shift (Wisconsin
card sorting test standard and modified versions), inhibition
(Stroop, Stop Signal Task, Go/no-Go), and cognitive flexibility
(phonological fluency), as well as memory, working memory,
attention, visuospatial abilities, and language.
Set-shifting and reward-related decision-making abilities are
important determinants of advantageous behavior, serving to
translate goals into action planning, as well as monitoring
response and errors (52).
Structural and functional neuroimaging outcomes were not
included in this meta-analysis, but neuroanatomical findings
in patients with abnormalities in set-shifting and reward-
related decision-making may help speculate on brain areas
that may undergo DRT overdose in PD. Lesion-symptom
mapping studies suggest reward-related decision-making to rely
upon an anatomical network composed of the ventromedial,
orbitofrontal and frontopolar cortices. Set-shifting, which is one
of the processes underlying cognitive control, depends on rostral
anterior cingulate cortex functioning (52). These brain areas form
part of the mesocorticolimbic system that, in the early stages of
PD, undergo less dopaminergic damage than the dorsal striatal
pathways.
According to the “overdose hypothesis,” the DRT amount
required to control motor symptoms in PD has the potential
to move the same patient away from the optimum for
certain cognitive functions (53). The relationship between the
efficiency of neuronal activity and the state of dopaminergic
modulation is represented by a Yerkes-Dodson inverted U-
shaped curve with cognitive functions declining with deviation
away from optimum dopamine levels, indicated by the center
of the curve (2). Extrapolating this model to set-shifting
and reward-related decision-making implies that DRT has the
capacity to both improve and impair these executive functions
depending on baseline dopamine levels in the underlying neural
circuitry. For patients with low baseline dopamine levels in
the mesocorticolimbic system, DRT may optimize activity as
supported by improved set-shifting and reward-related decision-
making when assessed in an optimally medicated state compared
to the same patients assessed following DRT withdrawal (54,
55). By the same token, if patients start out with higher
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FIGURE 7 | Forest plots for affective and motivational outcomes. Here are reported forest plots for depression (A), anxiety (B), anhedonia (C), apathy (D), and
impulsivity (E). Standardized mean difference represents Hedges’s g effect size. The size of the square indicates the weight of the study. The horizontal line represents
the 95% confidence interval. The diamond represents the pooled effect size. Negative effect sizes indicate worse performance in PD patients with ICD (ICD+) in
comparison to those without ICD (ICD−). ICD, impulse control disorder; PD, Parkinson’s disease.
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TABLE 3 | Results of the meta-analyses.
Random-effect model results Heterogeneity
Outcome K N SMD [95% CI] Z p X2 p I2(%)
Short-term verbal memory 10 736 −0.25 [−0.66, 0.16] 1.22 0.22 51.26 <0.00001 82
Short-term visuospatial memory 5 352 −0.12 [−0.42, 0.17] 0.82 0.41 5.26 0.26 24
Long-term verbal memory 9 702 −0.18 [−0.52, 0.16] 1.04 0.30 29.66 0.0002 73
Long-term visuospatial memory 3 322 −0.21 [−0.64, 0.21] 0.99 0.32 6.64 0.04 70
Working memory 7 371 −0.21 [−0.54, 0.13] 1.19 0.24 14.73 0.02 59
Attention 8 460 −0.22 [−0.47, 0.03] 1.73 0.08 9.40 0.23 26
Set-shifting 7 426 −0.49 [−0.78, −0.21] 3.37 0.0008 9.32 0.16 36
Concept formation (sort and shift) 7 434 −0.15 [−0.48, 0.19] 0.86 0.39 11.56 0.07 48
Concept formation (reasoning) 5 293 −0.21 [−0.56, 0.14] 1.16 0.25 5.66 0.23 29
Inhibition 11 677 −0.23 [−0.59, 0.12] 1.27 0.20 44.95 <0.00001 78
Cognitive flexibility 10 776 −0.02 [−0.25, 0.20] 0.19 0.85 16.79 0.05 46
Reward-related decision-making 8 238 0.42 [0.02, 0.82] 2.05 0.04 15.50 0.03 55
Visuospatial abilities 7 548 −0.30 [−0.69, 0.08] 1.57 0.12 24.86 0.0004 76
Language 2 144 −0.35 [−0.87, 0.17] 1.31 0.19 1.96 0.16 49
Depression 21 1431 0.35 [0.16, 0.54] 3.54 0.0004 51.42 0.0001 61
Anxiety 10 832 0.43 [0.18, 0.68] 3.39 0.0007 21.27 0.01 58
Anhedonia 2 309 0.26 [0.01, 0.50] 2.01 0.04 0.01 0.94 0
Apathy 4 386 0.42 [−0.04, 0.87] 1.81 0.07 9.09 0.03 67
Impulsivity 6 429 0.79 [0.50, 1.09] 5.26 <0.00001 8.89 0.11 44
K, number of studies; N, number of participants; SMD, standardized mean difference; CI, confidence interval. P values below the significance level (p < 0.05) are reported in italics.
mesocorticolimbic baseline levels of dopamine, DRT causes
dopamine over-activity in the mesocorticolimbic system. This
view is consistent with evidence that dopamine agonists increase
frontal cortex blood flow (56), and enhance reward-related risk-
taking behavior in ICD+ compared to ICD– (57).
A recent meta-analysis of case-control studies on the
prevalence of ICD in PD provides indirect evidence of
dopaminergic over-activity, as being medicated for PD and
disease duration were both factors that increased the risk of
ICD (58). As disease duration advances, the dopaminergic
degeneration spread to brain areas that were spared in the
early stages of the disease, such as prefrontal cortex (59). The
progressive involvement of brain areas during PD progression
may have two consequences. The first is a dysregulation
of brain regions involved in the top-down mechanisms of
cognitive control of behavior (60). The second is the need
to increase DRT dosage to compensate motor symptoms and
the consequent overstimulation of less damaged brain areas.
However, the relationship between ICD and DRT dosage is
not well-established; some studies report no difference between
DRT doses and ICD (18, 25, 61, 62), with others reporting
an association between ICD and dopamine agonists doses (63–
68). In this meta-analysis we lacked the power for conducting
moderator analysis for disease duration, total LEDD, LD LEDD,
and DA LEDD in reward-related decision-making and set-
shifting leaving this question unanswered.
Our data may help reconcile the debate whether ICD in
PD is associated with frontal lobe dysfunction (69–72). The
discrepancy between previous reports is likely due to differences
in the tasks and the underlying executive function subdomains
investigated. Our data indicate that some frontal tasks and
related subdomains may not be affected by ICD. Therefore,
neuropsychological evaluation of ICD+ patients should include
a broad range of executive function tasks, encompassing both
reward-related decision-making and set-shifting, and not be
limited to a general frontal screening test, such as the Frontal
Assessment Battery, which does not include those subdomains.
The profile of executive dysfunction we found confirms the
conclusions of a previous meta-analysis (33) that also reported
reduced abstraction/concept formation and visuospatial abilities
in ICD+. The discrepancy between the two meta-analyses can
be ascribed to our inclusion of two reports (18, 50) not available
at the time of the former one, and by our stricter exclusion
criteria. We excluded four studies included by Santangelo et al.
(7, 14, 58, 59), because of (a) patients with hypersexuality and
compulsive shopping included the ICD– group (7), (b) dementia
not excluded (14), and (c) patients screened for pathological
gambling (73) or punding (74) only, thereby the presence of other
ICDs in the ICD– group could not be ruled out.
Our secondary aim was to explore affective and motivational
outcomes associated with ICD, as evidence indicates a role for
dopamine dysregulation in the pathophysiology of impulsivity,
apathy, and anhedonia in pathological gambling, drug addiction,
and ICD+ (75–77). We found increased rates of self-reported
depression, anxiety, anhedonia, and impulsivity, but not apathy
in ICD+ compared to ICD–.
Impulsivity and apathy have been suggested to represent
opposite ends of a dopaminergic continuum, where the former
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FIGURE 8 | Funnel plots for cognitive, affective and motivational outcomes.
Here are reported funnel plots for short-term verbal memory (A), inhibition (B),
phonological fluency (C), depression (D), and anxiety (E). There is no evidence
to suggest publication bias.
and the latter are associated with hyper and hypodopaminergic
state, respectively (75). According to this view, DRT
mesocorticolimbic overstimulation increases impulsivity that, in
turn, may enhance reward-related behavior that, over time, may
become addictive in nature (78). The association between ICD+
and impulsivity but not apathy in our meta-analysis is consistent
with this model and the evidence that the D2 dopamine agonist
pramipexole improves apathy in PD patients without ICD (79)
but also increases impulsivity (1).
Anhedonia is defined as the decreased ability to experience
pleasure from positive stimuli (80). Pramipexole may reduce
anhedonia in ICD–, suggesting its hypodopaminergic nature
(81).
The co-occurrence of hypodopaminergic anhedonia with
hyperdopaminergic ICD is surprising. One possible explanation
is that ICD+ patients may have decreased ability to experience
pleasure when not engaged in ICD. This hypothesis is
supported by the evidence that people addicted to alcohol
or drugs experience anhedonia during withdrawal syndrome,
a feature that may facilitate relapse (82). However, the
relationship between anhedonia and dopaminergic states is not
so straightforward and anhedonia is also recognized as one of the
overlapping symptoms between apathy and depression (83). The
association with anhedonia may be confounded by the presence
of depression, which in some cases might be serotoninergically
mediated (84). However, there are only two studies and further
investigation is needed.
The pathophysiology of depression and anxiety in PD is
likely to be multifactorial including reaction to disease diagnosis
and anxiety about its future course. Depression and anxiety are
present in the premorbid PD stage (85), therefore suggesting
they may represent a core feature of PD. In our meta-analysis
depression and anxiety levels were higher in ICD+ compared
to ICD–. ICD may have a negative impact on the quality of
life (21, 25), and in turn increase depression and anxiety levels.
Also, as the mesocorticolimbic pathways dysfunction may be
involved in depression, anxiety and ICD, they might co-occur as
epiphenomena of shared neural correlates (40).
The main limitation of this meta-analysis is the small
number of studies, most of which with small samples that
might have contributed to high heterogeneity for some of the
outcomes explored. This consideration could be reflected in
the sensitivity analysis data for long-term visuospatial memory,
working memory, attention, inhibition, reward-related decision-
making, apathy, and it suggests caution in the interpretation of
the results for these outcomes. Moreover, the inclusion in the
same domains of tasks that might involve different cognitive
processes could have contributed to the high heterogeneity and
the low stability of some results. However, considering the single
cognitive task would have resulted in a reduction of the power,
because of the low number of studies using the same tasks.
Unfortunately, we were not able to perform separate analyses for
dopamine agonists and levodopa, as the majority of the studies
included patients who were under both types of DRT. Due to
the small number of studies, moderator analysis for levodopa
and dopamine agonist LEDDwas performed for depression only,
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TABLE 4 | Results of the moderator analysis.
Short-term verbal memory Inhibition Cognitive flexibility Depression Anxiety
Moderators K β p K β p K β p K β p K β p
Age 9a – – 11 −0.003 0.970 8a – – 19 −0.029 0.183 8a – –
Education 8a – – 10 −0.050 0.669 6a – – 10 −0.055 0.332 6a – –
PD Duration 8a – – 10 0.045 0.645 9a – – 19 −.012 0.810 8a – –
H and Y 8a – – 8a – – 6a – – 14 −0.153 0.570 7a – –
UPDRS–III 10 0.073 0.081 11 0.018 0.578 10 −0.005 0.799 19 −0.009 0.557 9a – –
Total LEDD 9a – – 10 0.002 0.200 9a – – 19 0.000 0.992 9a – –
DA LEDD 9a – – 9a – – 8a – – 18 0.001 0.435 9a – –
LD LEDD 4a – – 5a – – 3a – – 10 0.000 0.749 6a – –
PD, Parkinson’s disease; H and Y, Hoehn and Yahr score; UPDRS–III, unified Parkinson’s disease rating scale part III (motor subscale) score; LEDD, levodopa equivalent daily dosage
(mg); DA, dopamine agonist; LD, levodopa; K, number of studies. anot included in the moderator analysis because k<10.
which showed no effect. This is not surprising, as in the larger
study published so far, ICDs were found to be associated either
with dopamine agonists or, to a lesser extent, with levodopa (1).
These data are in keeping with the notion that both levodopa and
dopamine agonists can interfere with the phasic and tonic activity
of dopaminergic neurons (86) that, by facilitating neuroadaptive
changes in dopaminergic system functioning, may predispose to
ICD.
Another limitation is the inclusion of cross-sectional studies
that impede the exploration of the direction of the cause-
effect relationship between cognitive, affective and motivational
outcomes and ICD; therefore multi-center and longitudinal
studies are needed. Moreover, even if we excluded studies
focusing on punding and dopamine dysregulation syndrome
only, these conditions were present in many studies, and
probably contributed to high heterogeneity for some outcomes.
Furthermore, 23/25 studies did not mention assessors to
be blind to the ICD status and this might have affected
tools administration and scoring. Future studies should be
conducted following blinding procedures. Finally, QUIP, a
validated screening instrument with high sensitivity (94%) but
low specificity (72%) to ICD in PD (87) was used in two studies
(18, 25), possibly leading to false positive and/or subclinical
ICD inclusion. Still unanswered questions include whether
set-shifting and reward-related decision-making abnormalities
in PD patients with ICD reflect structural and functional
mesocorticolimbic changes due to acute or chronic DRT effects,
or whether they can revert following ICD treatment and
remission. Future studies should address these points, since
better understanding ICD pathophysiology may help tailoring
treatment of ICD+.
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